- Home
- HPP vs MNMD Comparison
HPP vs MNMD Comparison
Compare HPP & MNMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- HPP
- MNMD
- Stock Information
- Founded
- HPP 1997
- MNMD 2019
- Country
- HPP United States
- MNMD United States
- Employees
- HPP N/A
- MNMD N/A
- Industry
- HPP Real Estate
- MNMD Pharmaceuticals and Biotechnology
- Sector
- HPP Finance
- MNMD Health Care
- Exchange
- HPP Nasdaq
- MNMD Nasdaq
- Market Cap
- HPP 940.3M
- MNMD 960.2M
- IPO Year
- HPP 2010
- MNMD N/A
- Fundamental
- Price
- HPP $2.44
- MNMD $14.20
- Analyst Decision
- HPP Hold
- MNMD Strong Buy
- Analyst Count
- HPP 11
- MNMD 7
- Target Price
- HPP $3.04
- MNMD $26.71
- AVG Volume (30 Days)
- HPP 4.2M
- MNMD 2.1M
- Earning Date
- HPP 11-05-2025
- MNMD 11-06-2025
- Dividend Yield
- HPP N/A
- MNMD N/A
- EPS Growth
- HPP N/A
- MNMD N/A
- EPS
- HPP N/A
- MNMD N/A
- Revenue
- HPP $792,977,000.00
- MNMD N/A
- Revenue This Year
- HPP N/A
- MNMD N/A
- Revenue Next Year
- HPP $6.87
- MNMD N/A
- P/E Ratio
- HPP N/A
- MNMD N/A
- Revenue Growth
- HPP N/A
- MNMD N/A
- 52 Week Low
- HPP $1.78
- MNMD $4.70
- 52 Week High
- HPP $4.67
- MNMD $14.43
- Technical
- Relative Strength Index (RSI)
- HPP 39.32
- MNMD 68.58
- Support Level
- HPP $2.31
- MNMD $12.60
- Resistance Level
- HPP $2.52
- MNMD $13.74
- Average True Range (ATR)
- HPP 0.12
- MNMD 0.92
- MACD
- HPP -0.01
- MNMD 0.03
- Stochastic Oscillator
- HPP 27.51
- MNMD 91.99
About HPP Hudson Pacific Properties Inc.
Hudson Pacific Properties Inc is a real estate investment trust that acquires, operates, and owns office buildings and media and entertainment properties, such as sound stages, on America's West Coast. The company focuses on developed, urban markets in Northern California, Southern California, and the Pacific Northwest. In terms of total square footage, the vast majority of Hudson Pacific's real estate portfolio is composed of office properties located in the Greater Seattle, San Francisco, and Los Angeles areas. The company operates in two reportable segments; office properties & related operations; and studio properties & related operations. The majority of revenue is derived from the office properties & related operations segment.
About MNMD Mind Medicine (MindMed) Inc.
Mind Medicine Inc. is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. It is developing a pipeline of product candidates targeting neurotransmitter pathways that play key roles in brain health disorders. This includes explicitly pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM120 and MM402, as its key product candidates. The MM120 is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that is being developed to treat generalized anxiety disorder and clinical depressive disorder, and the MM402 is a proprietary form of the R-enantiomer of 3,4-methylenedioxymethamphetamine (MDMA), being developed to treat autism spectrum disorder (ASD).